Telehealth names Ro, Hims, HelloDrUSA as channels

Ro, Hims and HelloDrUSA surfaced on May 14 in social posts and company marketing as online routes for people seeking GLP-1 weight-loss treatment. The companies were presented not as manufacturers, but as telehealth channels that connect patients with licensed clinicians who can evaluate, prescribe and arrange fulfillment if a patient qualifies. Company websites reviewed on Thursday show all three currently market weight-loss care built around semaglutide, tirzepatide or other GLP-1-related options. The posts landed in a market that has shifted since the U.S. Food and Drug Administration said semaglutide injection shortages were resolved on February 21, 2025, after previously determining tirzepatide injection shortages were resolved in late 2024. Those decisions narrowed the shortage-based opening that had allowed large-scale compounding to expand during earlier supply disruptions, even as telehealth platforms continued to advertise online intake, membership and prescription support. (ro.co) ### What exactly are Ro, Hims and HelloDrUSA offering? Ro says on its website that it connects patients with U.S.-licensed professionals entirely online and offers weight-loss treatment that can include GLP-1 medication if appropriate. Ro’s weight-loss pages on Thursday listed Wegovy pill, Wegovy pen, Zepbound, Ozempic and Foundayo among available options, with insurance or cash-pay routes depending on the product. Hims says its weight-loss program includes a membership, clinician access and GLP-1 medications if prescribed. (fda.gov) Hims’ current weight-loss page listed Wegovy Pill from $149 a month, Wegovy Pen from $199, Zepbound Vial from $299, Ozempic from $199 and Mounjaro or Zepbound at higher listed prices, with a separate membership fee of $39 for the first month and $149 a month after that. HelloDrUSA says on its weight-management page that it offers doctor-guided GLP-1 treatments, including semaglutide and tirzepatide. (ro.co) The site presents the service as a telehealth pathway rather than a dispensing manufacturer or pharmacy. ### Are these companies selling the drugs themselves? Ro and Hims describe themselves as telehealth platforms that connect patients to licensed providers and support prescription access, rather than as the original drugmakers. (hims.com) Ro says treatment is “100% online” and refers to “real providers” and “FDA-approved options.” Hims says medication is available only if a licensed provider determines a patient is eligible and medically appropriate. (hellodrusa.com) That distinction matters because branded GLP-1 medicines such as Wegovy, Ozempic, Zepbound and Mounjaro are made by Novo Nordisk or Eli Lilly, while telehealth companies market the intake, care-management and fulfillment pathway around those products. Hims’ materials also say the company is not affiliated with Eli Lilly. ### Where does compounding fit into the picture now? The FDA says compounded drugs are not FDA-approved and may be appropriate when a patient’s medical need cannot be met by an approved drug or when the approved drug is not commercially available. (ro.co) The agency has also published safety concerns about unapproved GLP-1 drugs used for weight loss and said it had received hundreds of adverse-event reports tied to compounded semaglutide and compounded tirzepatide as of July 31, 2025. (hims.com) FDA records show semaglutide injection shortages were marked resolved in February 2025, and tirzepatide injection shortages were determined resolved in December 2024 after reevaluation. The agency said last week it is proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound those drugs from bulk substances. (fda.gov) Hims has publicly acknowledged that market shift. In a March 2026 investor release, Hims & Hers said the U.S. weight-loss market had changed as a broader range of FDA-approved GLP-1 treatments became available at lower prices, and that it was shifting its U.S. offering toward branded GLP-1 access while still offering compounded GLP-1s through personalized dosing pathways where providers determine it is clinically appropriate. (fda.gov) ### Why are social posts naming telehealth channels at all? May 14 social posts naming Ro, Hims and HelloDrUSA reflected how patients increasingly shop for access routes, not just drug names. Company sites now compete on intake speed, cash-pay pricing, insurance support, membership structure and whether they offer pills, pens, vials or off-label prescribing pathways where permitted. March 26, 2026, provides one clear example of that positioning. (investors.hims.com) Hims & Hers said that day it was offering direct access to Wegovy pills, Wegovy injections and Ozempic injections at all dosage levels, and paired that launch with a new membership model and 24/7 care-team access. ### What should readers watch next? The FDA’s shortage database and compounding policy notices are the clearest public markers for whether access routes tighten or reopen. (ro.co) Company product pages for Ro, Hims and HelloDrUSA are also likely to change as pricing, eligible states, branded supply and prescribing terms shift. Hims’ investor site lists first-quarter 2026 earnings materials this month, and FDA rulemaking on the proposed 503B bulks exclusion will provide another named milestone for the telehealth and compounding market. (news.hims.com) (investors.hims.com) (fda.gov)